← All trials
NCT06642844
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 30, 2024
- Primary completion
- Oct 30, 2028
- Completion date
- Oct 30, 2029
- First posted
- Oct 15, 2024
- Last posted
- Oct 15, 2024
- Enrollment
- 244
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University Hospital, ToursLead sponsor
- University of LorraineCollaborator
- Rouen Normandy UniversityCollaborator
- University Clermont AuvergneCollaborator
- Institut Paoli-CalmettesCollaborator
- University of NantesCollaborator
- University of Picardie Jules VerneCollaborator
- University of Caen-NormandieCollaborator
- University of RennesCollaborator
- University of ReimsCollaborator
- University of Western BrittanyCollaborator
- Institut Gustave RoussyCollaborator
- University of PoitiersCollaborator
- University of ToulouseCollaborator
- University of BurgundyCollaborator
- University of Franche-ComtéCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.